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obese class III (OR: 0.399, 95% CI: 0.228 – 0.698) smokers were less likely to be
prescribed cessation medications compared to those with normal weight. The
weight spline had a significant decrease in the interval of overweight (OR: 0.853,
95% CI: 0.729-0.999). Male smokers, aged  65 years, white race, having private
insurance, having depression, cardiovascular diseases diagnosis, and tobacco
counseling, were significant predictors of having a smoking cessation prescription.
CONCLUSIONS: Overweight or obese smokers were less likely to be prescribed
cessationmedications. Future research is needed to investigate the reasons behind
this difference and develop interventions to help overweight and obese smokers
quit.
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OBJECTIVES: Narcotic medications are increasingly becoming the most-abused
medicines in the United States, accounting for hundreds of deaths and thousands
of emergency room visits. The objective of this study is to examine the use of
narcoticmedications in a commercially insured population.METHODS: Retrospec-
tive pharmacy claims from a large US pharmacy benefit manager between January
2010 to December 2010 examined the prevalence, utilization and cost trend of
narcotic medications (GPI265). Only commercially insured patients with inte-
grated and funded prescription benefits were included in the analysis. RESULTS:
While females filled more narcotic prescriptions than males, male patients used
more expensive narcotic medications than their female counterparts ($58 per
script and $45 per script, respectively). The largest difference in cost per prescrip-
tion betweenmales and femaleswas in the 25-34 age groups ($64 per script and $33
per script for male and female, respectively). Within this age group, males spent
42% of their overall narcotic cost on Suboxone® and 16% on Oxycontin®, whereas
females only spent 21% on Suboxone®, 15% on hydrocodone-acetaminophen, and
14% on Oxycontin®. Males had lower generic fill rate (GFR) compared to their
female counterparts (86% and 95%, respectively). Consequently, the Per Member
per Year (PMPY) narcotic cost for males was $13.04 higher than females 24-35
years of age. As patient age increases, however, the trend is reversed: female
PMPY narcotic cost is $19.35 higher thanmale counterparts aged 75 or older. The
utilization and cost of narcotic medications differ by geographic region with
Oklahoma, Nevada, Utah, Ohio, and Alabama ranked as the Top 5 most costly
and Alabama, Oklahoma, Tennessee, Mississippi, and Wyoming having the
highest utilization. CONCLUSIONS:Results from this analysis can provide insights
into the utilization and cost of narcotic medications.
PSY52
IS ANTI-OBESITY MEDICATION (AOM) USE MEDICALLY OR SOCIALLY DRIVEN?
AN ANALYSIS OF PREDICTORS OF AOM USE AMONG OVERWEIGHT AND OBESE
FEMALE MEPS RESPONDENTS
Alipoe A1, Hong SH2
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee,
Memphis, TN, USA
OBJECTIVES: Currently, little is known about anti-obesity medication (AOM) utili-
zation. The purpose of this research was to explore predictors of utilization among
overweight and obese females within the MEPS database and to determine
whether use is primarily socially or medically driven. METHODS: A retrospective
case-control study design using 2003-2008 data from the Medical Expenditure
Panel Survey (MEPS) was performed. Datasets were generated by linking Full-Year
Consolidated Files to Prescribed Medicine Files in MEPS for each year. The Condi-
tions Files for each year were linked to ascertain whether or not respondents pos-
sessed a comorbidity of interest (diabetes, hyperlipidemia, hypertension). TheMul-
tum Lexicon File, released in Fall 2003, was used to identify AOM users in MEPS.
Logistic regression analysis was used to indicate whether obese/overweight re-
spondents take anAOM in that year, controlling for indicated medically necessary
or socially desirable related variables, and other potentially significant variables.
Proc means and proc freq in SAS 9.1 were used to generate descriptive statistics.
RESULTS: LR results show thatwomenwho are above the age of 35 are significantly
less likely to consume anti-obesity medications (Ages 36-49, OR0.570, p0.0082;
Ages 50-64, OR0.366, p0.001); oldest females are least likely to consume them
(Ages 65, OR0.072, p0.001). Married females are significantly more likely to
consume anti-obesity medications (OR1.695, p0.003). With unit increases in
BMI, females are 1.03 (p0.001)more likely to take anti-obesitymedications. Other
significant variables included education and possession of private insurance.
Dummy variables representing comorbidities were not significant predictors of
AOM use. CONCLUSIONS: Consumption of anti-obesity medications may be more
socially- rather than medically-driven, with more socially-related variables ap-
pearing significant in the model. Increased monitoring patients who receive these
medications is of urgent importance. AOMuse potentially involves adverse effects;
physicians’ role in prescribing these potentially dangerous medications may need
to be addressed.
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OBJECTIVES: Oxycodone controlled-release (CR) and oxymorphone extended-re-
lease (ER) are commonly prescribed, long-acting opioids, approved for twice-daily
dosing. We compared Daily Average Consumption (DACON) for oxycodone CR and
oxymorphone ER before and after the introduction of reformulated oxycodone CR.
METHODS: This was a retrospective claims database analysis using pharmacy
claims from the MarketScan® database during January 2010 through March 2011.
The Interrupted time series analysis was used to evaluate the impact of the intro-
duction of reformulated oxycodone CR on DACON of both drugs. RESULTS: Before
the introduction of reformulated oxycodone CR, the mean DACON for oxycodone
CR was higher than the mean DACON for oxymorphone ER in both highest and all
lower strengths pairs by 0.51 and 0.46 tablets, respectively. After the introduction,
the difference in mean DACON between the two drugs became 0.45 tablets for the
highest and 0.40 tablets for the lower strengths. Interrupted time series results
demonstrated that the immediate and overall impact on DACON of the reformu-
lated oxycodone CR was minimal, while there were no changes in the DACON for
oxymorphone ER as a result of the introduction. The estimated difference in aver-
age DACON for oxycodone CR decreased by 0.1 tablets or 3.7% (P 0.001) 6 months
after the new formulation was introduced. CONCLUSIONS: Mean DACON was
higher for oxycodone CR compared to oxymorphone ER by 0.4 tablets per day for all
dosage strengths for the entire study period. After the introduction of reformulated
oxycodone CR, the DACON for oxycodone CR was slightly mitigated; however,
there was a minimal impact on the mean difference between oxycodone CR and
oxymorphone ER.
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OBJECTIVES: Hospital admissions are frequent for Crohn=s Disease (CD) patients,
either to treat a flare-up or to have surgery. There are few data about CD in Latin
America. Some studies, however, have pointed to an increase in the prevalence
across the years. The aim of current the study is to analyze trends of the hospital
admission rate by CD in three Latin American countries: Brazil, Chile and Mexico.
METHODS: Data from the years 2001 to 2008 on primary diagnosis of Crohn=s
Diseasewere taken fromDatabases of Hospital Admission in Public Health System:
DATASUS in Brazil, DEIS in Chile and SINAIS in Mexico. Numbers of hospital ad-
mission by country, year and age rangewere collected andweighted by age specific
country population. Trends in hospital admission rates over timewere analyzed by
Poisson general estimation equations with an autoregressive correlation matrix.
Estimated coefficients were considered significant when p0.05. RESULTS: In all
countries the rate increased with the age. Mexico had the lower rates, which re-
main nearly constant over the years (0.09/100,000 inhabitants, pNS). In Chile, the
rate has increased over the years (0.45; annual risk ratio: 1.568 p0.001), differ-
ent fromBrazil that showed a decrease (-0111; annual risk ratio0.893; p0.001).
CONCLUSIONS: Reports from reference centers showed an increase in the number
of cases in the three countries; however in Mexico the number of patients still very
low. Therefore, the trend of hospital admission rates in Chile and Mexico seem to
be similar as the reported disease frequency. Regarding Brazil, a possible explana-
tion for the decrease in hospital admission could be changes in treatment prac-
tices, the financing of biological therapies in Public Health System since 2002. The
trends of hospital admission vary across the Latin America countries, and national
assistance programs for CD seem to have an impact on hospital admission rate.
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OBJECTIVES: The objective of this research was to conduct primary research with
US managed care decision-makers to understand their perceptions and manage-
ment expectations for pending biosimilar market availability in the United States.
METHODS: Explorative primary research (n20) was conducted with a sample of
Managed Care Organization (MCO) decision-makers composed of pharmacy and
medical directors, clinical pharmacists, and field experts involved in evaluating
expectations of biosimilar management. Interviews were conducted from January
to March 2011 and consisted of individual one-hour phone cponversations. Survey
development focused on addressing how biosimilar evaluations for plan coverage
will be made and vary by therapeutic class including testing of: Erythropoietin-
stimulating agents (ESA), cancer monoclonal antibodies (mAb), anti-tumor necro-
sis factor agents (anti-TNF), and granulocyte-colony stimulating factors (G-CSF).
Baseline knowledge that US payers had about biosimilars and abbreviated pathway
development was also tested. Qualitative survey methods for eliciting stated pref-
erences were used. RESULTS: Payers recognize differences between biosimilars
and small molecule generics in molecular structure andmanufacturing processes;
however, uncertainty exists around exact payer definitions for biosimilarity. Pay-
ers view biosimilars as alternative branded products rather than small molecule
generics. Research also indicated that contrary to review for small molecule gener-
ics, formulary review for biosimilar products will likely vary by class since different
drugs and indications may require different evidence. Specifically, variance in bio-
similarmanagement decisions will vary depending on the sensitivity level toman-
age the category. Payers expect biosimilar cost offsets within the range of 11-30%
from innovator brands. CONCLUSIONS: Presently, discussions about biosimilar
formulary review have been informal and high-levelt. Biosimilar product value
assessments will differ from the case of small molecule generics and coverage
policies will vary by class. Budgetary and economic impact is the major driver in
proposed utilization management controls, but will need to be balanced in light of
product comparisons in safety and efficacy.
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